Boston Scientific, a manufacturer of medical devices, completed the acquisition of BTG, a company which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of $11 per share. The total cash consideration for 100% of BTG's equity is c. $4.35bn. "Boston Scientific shares our commitment to transforming patient care, and has a sustained track record of innovation, clinical expertise and global commercial capabilities. The combined organization will be well positioned for success, enabling our valuable products to make a real difference to more people around the world," Dame Louise Makin, BTG CEO.